Renovacor, Inc.

Renovacor, Inc. , based in the US, focuses on developing innovative gene therapies for cardiovascular diseases, aiming to address critical unmet medical needs. Founded in 2013 and headquartered in Greenwich, US, Renovacor, Inc. specializes in gene therapies targeting cardiovascular conditions.

The firm was acquired by Rocket Pharmaceuticals, Inc. for USD 53 mn in stocks on September 21, 2022, to enhance their cardiology focus. The company has completed a total of 4 deals since its inception. The current CEO is Maggie Cook, while the founder, Arthur Feldman, has a notable history in the industry.

Renovacor, Inc. primarily develops gene therapies aimed at treating various cardiovascular diseases. The company's innovative approaches outline a clear pathway to address existing medical challenges in this therapeutic area, facilitating advancements in patient care and treatment efficacy. Renovacor, Inc.

has raised a total of USD 11. 05 mn through prior funding rounds, which primarily support its R&D initiatives and operational expenses to further its mission in gene therapy. Renovacor, Inc. is strategically positioned for growth by focusing on the development of new gene therapy products targeting cardiovascular diseases, with plans to introduce these therapies in the next few years.

The company aims to expand into international markets, particularly in Europe and Asia. The recent funding from Rocket Pharmaceuticals, Inc. will be utilized to enhance research capabilities and accelerate the development of key therapeutic assets.